Emerging agents for the treatment of mantle cell lymphoma.

Abstract:

:The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been conducted in MCL patients. In young patients, initial intensive therapy with high-dose cytarabine followed by high-dose chemotherapy and hematopoietic stem cell reinfusion has resulted in prolonged progression-free survival. In elderly subjects, who always represent a more heterogeneous group of patients, there is no consensus concerning which drugs can be used during induction chemotherapy. New drugs have essentially been evaluated in patients with recurrent disease or refractory to first-line regimens. Recently, two of them (bortezomib and temsirolimus) with different modes of action were registered in MCL. Targeted therapies are also being investigated extensively in MCL and are yielding interesting activities.

authors

Camara-Clayette V,Hermine O,Ribrag V

doi

10.1586/era.12.99

subject

Has Abstract

pub_date

2012-09-01 00:00:00

pages

1205-15

issue

9

eissn

1473-7140

issn

1744-8328

journal_volume

12

pub_type

杂志文章,评审
  • Monoclonal antibodies as an addition to current myeloma therapy strategies.

    abstract:INTRODUCTION:Immunotherapy has emerged as a major class in the therapeutic arsenal of multiple myeloma. Cell-based immunotherapy (CAR T-cells) and monoclonal antibody-based immunotherapy (naked monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell engagers) are the two cornerstones of this novel approa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1837627

    authors: Jullien M,Touzeau C,Moreau P

    更新日期:2020-10-26 00:00:00

  • Management of residual masses in testicular germ cell tumors.

    abstract:INTRODUCTION:About 50% of all patients with advanced testicular cancer demonstrate residual retroperitoneal or extraretroperitoneal masses. About two thirds of the masses harbour necrosis/fibrosis only whereas as about 10% and 40% harbour vital cancer or teratoma. Appropriate therapy will result in a high cure rate if ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1580146

    authors: Heidenreich A,Paffenholz P,Nestler T,Pfister D

    更新日期:2019-04-01 00:00:00

  • Predicting survival in chronic lymphocytic leukemia.

    abstract::There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.2

    authors: Bazargan A,Tam CS,Keating MJ

    更新日期:2012-03-01 00:00:00

  • Current concepts and future strategies in the management of intracranial germinoma.

    abstract::Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.856268

    authors: Kortmann RD

    更新日期:2014-01-01 00:00:00

  • Postoperative nodal irradiation in breast cancer patients with 1 to 3 axillary lymph nodes involved: the debate continues….

    abstract::Regional lymph node irradiation is usually indicated in patients with positive node breast cancer. However, there are some controversies regarding the clinical benefits of adding regional nodal irradiation to whole-breast or thoracic-wall irradiation after breast surgery especially for patients with 1 to 3 positive ax...

    journal_title:Expert review of anticancer therapy

    pub_type: 社论

    doi:10.1586/14737140.2015.1106317

    authors: Marta GN,de Moraes FY

    更新日期:2015-01-01 00:00:00

  • Salvage of local recurrence after primary thermal ablation for small renal masses.

    abstract::The management of renal tumors has evolved rapidly over the last two decades, with the ascendance of nephron-sparing surgery (NSS), largely spurred by the increased incidental detection of small renal masses (SRMs) and evidence that preservation of renal parenchyma reduces the risk of chronic kidney disease. The field...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.12.1899

    authors: Nguyen CT,Campbell SC

    更新日期:2008-12-01 00:00:00

  • Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer.

    abstract::Whereas radical cystectomy is the standard of care in high-grade, invasive bladder tumors, the extent of lymphadenectomy and its diagnostic and/or therapeutic potential is controversial. Independent predictors for lymph node involvement are T-stage, histological grading and lymphovascular invasion. Preoperative assess...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.6.871

    authors: Nagele U,Anastasiadis AG,Merseburger AS,Sievert KD,Stenzl A,Kuczyk M

    更新日期:2006-06-01 00:00:00

  • CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.

    abstract::Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbocicli...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1852934

    authors: Onesti CE,Jerusalem G

    更新日期:2020-12-13 00:00:00

  • End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.

    abstract::In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological pattern...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.164

    authors: Franceschi E,Agati R,Brandes AA

    更新日期:2011-11-01 00:00:00

  • Current and emerging treatments in the management of castration-resistant prostate cancer.

    abstract::Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In addition to cytotoxic chemotherapy, treating physicians and their patients now have the option of several new agents that tar...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.59

    authors: Shapiro D,Tareen B

    更新日期:2012-07-01 00:00:00

  • Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.

    abstract::This review summarizes the safety of sorafenib, an oral multikinase inhibitor, focusing on the randomized, placebo-controlled, Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) in renal cell carcinoma, which formed the basis of the approval of sorafenib. Similar to other targeted agents, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1193

    authors: Hutson TE

    更新日期:2007-09-01 00:00:00

  • Pioneering the trail of cancer immunotherapy.

    abstract::The annual conference of the International Society for Biological Therapy of Cancer (iSBTc), recently renamed the Society for Immunotherapy of Cancer (SITC), provides clinicians and scientists with a uniquely broad yet focused view of the growing field of tumor immunology and cancer immunotherapy. In this time of exci...

    journal_title:Expert review of anticancer therapy

    pub_type:

    doi:10.1586/era.10.229

    authors: Kotlan B,Balwit JM

    更新日期:2011-03-01 00:00:00

  • An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas.

    abstract:BACKGROUND:Published data concerning primary mediastinal sarcomas are limited to small-sized retrospective series.  This study reviewed the clinical outcomes of these cases from the SEER (surveillance, epidemiology and end results) database. METHODS:Primary mediastinal sarcomas (1988 - 2013) were assembled from the SE...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2017.1378576

    authors: Abdel-Rahman O

    更新日期:2017-11-01 00:00:00

  • Role of PET/PET-CT in the management of sarcomas.

    abstract::Positron emission tomography (PET) is a functional diagnostic imaging technique that provides very different information from that obtainable with other imaging modalities. The most widely used radiotracer is F-18 fluoro-2-deoxy-D-glucose (FDG), which is an analog of glucose. The FDG uptake in cells is directly propor...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.8.1241

    authors: Kumar R,Chauhan A,Vellimana AK,Chawla M

    更新日期:2006-08-01 00:00:00

  • Anticancer drug development based on modulation of the Bcl-2 family core apoptosis mechanism.

    abstract::Cancer cells generally maintain their survival by suppressing apoptosis. Mitochondrial mechanisms are involved in most forms of apoptosis (referred to as mitochondrial apoptosis), and the Bcl-2 family controls apoptosis at the mitochondrion via a balance of the effects of pro- and antiapoptotic members. Antiapoptotic ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.6.1157

    authors: Gardner CR

    更新日期:2004-12-01 00:00:00

  • Statistical approaches for evaluating body composition markers in clinical cancer research.

    abstract:INTRODUCTION:The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review st...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1298446

    authors: Bayar MA,Antoun S,Lanoy E

    更新日期:2017-04-01 00:00:00

  • Current radiotherapy techniques in NSCLC: challenges and potential solutions.

    abstract::Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1760094

    authors: Giaj-Levra N,Borghetti P,Bruni A,Ciammella P,Cuccia F,Fozza A,Franceschini D,Scotti V,Vagge S,Alongi F

    更新日期:2020-05-01 00:00:00

  • The role of the microbiome in drug resistance in gastrointestinal cancers.

    abstract::Introduction: The microbiota is recognized for its impact on both human health and disease. The human microbiota is made up of trillions of cells, including bacteria, viruses, and fungi. The largest population of microbes reside in the gut, prompting research for better understanding of the impact of gastrointestinal ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1844007

    authors: Garajová I,Balsano R,Wang H,Leonardi F,Giovannetti E,Deng D,Peters GJ

    更新日期:2020-12-08 00:00:00

  • Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.

    abstract::Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer se...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.4.489

    authors: Braun MS,Quirke P,Seymour MT

    更新日期:2007-04-01 00:00:00

  • Highlights of the 2nd European Lung Cancer Conference.

    abstract::The Second European Lung Cancer Conference was held in Geneva, Switzerland from 28 April to 1 May 2010, under the cosponsorship of the International Association for the Study of Lung Cancer and the European Society for Medical Oncology. The main topics included: tobacco control, which represents a crucial challenge fo...

    journal_title:Expert review of anticancer therapy

    pub_type:

    doi:10.1586/era.10.93

    authors: Girard N,Mornex F

    更新日期:2010-07-01 00:00:00

  • Review of management issues in relapsed osteosarcoma.

    abstract::Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.863453

    authors: Vijayamurugan N,Bakhshi S

    更新日期:2014-02-01 00:00:00

  • Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review.

    abstract::Neurocognitive function (NCF) impairment is an important component of primary and metastatic brain tumors and their therapeutic interventions. As a result, modern clinical trials of cranial irradiation for adult cancer patients have incorporated NCF testing as a primary or secondary end point. In doing so, these clini...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.34

    authors: Caine C,Mehta MP,Laack NN,Gondi V

    更新日期:2012-05-01 00:00:00

  • The evolving role of radiotherapy in treatment of oligometastatic NSCLC.

    abstract::Non-small cell lung cancer (NSCLC) patients with metastases limited in site and number, termed oligometastases, may represent a unique subpopulation of advanced NSCLC with improved prognosis. The optimal management of these patients remains unclear with the treatment approach currently undergoing a paradigm shift. The...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1105745

    authors: Bergsma DP,Salama JK,Singh DP,Chmura SJ,Milano MT

    更新日期:2015-01-01 00:00:00

  • New treatment strategies for malignant gliomas.

    abstract::Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.7.1087

    authors: Sathornsumetee S,Rich JN

    更新日期:2006-07-01 00:00:00

  • Role of MRI for staging of rectal cancer.

    abstract::Total mesorectal excision has been established as a standard surgical procedure for rectal cancer. MRI is now routinely used for preoperative staging of rectal cancer and provides accurate assessment of the tumor relative to the circumferential margin, that is, the mesorectal fascia. This identifies patients at risk o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.13

    authors: Jhaveri KS,Sadaf A

    更新日期:2009-04-01 00:00:00

  • Advances in diagnosis and management of oligodendroglioma.

    abstract::Oligodendrogliomas are primary brain tumors, genetically characterized by chromosomal alterations in the 1p and 19q. Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years. The response rate in mixed oli...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.5.520

    authors: Hussein MR,Baidas S

    更新日期:2002-10-01 00:00:00

  • Colon and rectal cancer after renal transplantation.

    abstract::Increased cancer risk after renal transplantation is believed to be a consequence of continuous immunosuppression. However, the risk of colorectal cancer (CRC) after renal transplantation is controversial and has received limited study. Accumulating evidence suggests that colon and rectal cancers have different charac...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.8.1339

    authors: Kan M,Gill JS,Wiseman SM

    更新日期:2008-08-01 00:00:00

  • Management of Merkel cell carcinoma.

    abstract::Merkel cell carcinoma is an uncommon cutaneous malignancy. Although it is rare, Merkel cell carcinoma has been described as the most malignant primary skin tumor. It is therefore important that once diagnosed, Merkel cell carcinoma is treated appropriately. The aim of this short review is to provide a summary of the a...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.1.3.441

    authors: Plunkett TA,Subrumanian R,Leslie MD,Harper PG

    更新日期:2001-10-01 00:00:00

  • Aromatase inhibitors in breast cancer therapy.

    abstract::Estrogens are involved in numerous physiological processes and have crucial roles in certain disease states, such as mammary carcinomas. Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase. Aromatase is found in breast tissue and the i...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.2.181

    authors: Brueggemeier RW

    更新日期:2002-04-01 00:00:00

  • Colorectal cancer stem cells and their implications for novel anticancer therapy.

    abstract::Anticancer therapy relies on targeting highly proliferative cells. Commonly used chemotherapy does not selectively target individual cancer cells. The identification of distinct cancer stem cells that have the unique ability to engraft tumors and maintain cancer self-renewal may prove vital in the development of novel...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.13.17

    authors: Klotz D

    更新日期:2013-04-01 00:00:00